Bibliographic record and links to related information available from the Library of Congress catalog
Note: Electronic data is machine generated. May be incomplete or contain other coding.
Part I: Pharmaceutica industry, profts and obligations 1 The pharmaceutical industry and the pursuit of profit 11 Joel Lexchin 2 Social, ethical, and legal issues in drrug development, marketing, and pricng policies: setting priorities: pharmaceuticals as private organizations and the duty to make money/mnaximize profits 25 Kristina Mi. Lybecker 3. The pharmaceutical industry and its obligations in the dereloping world 32 Ann Vills, Patricia Werhane, and Mithael Gorman 4 Drug tcompanies as organizational hybrids 41 Varren Kaplan 5. Physicians and the pharmaceutical industry: a symbiotic relationship? 57 lan E Marsihall . Industry perspectives on equity, access, and corporate social responsibility: a view from the inside 65 Robert.A. Freeman Part i: Justice medicines as glba public goods . Pharnmaeuticals, public health, and the law a public health perspectie 77 Wren . E Pannet 8 knccss to medications and global justice 88 David B. Resnik 9. Pharmacogenetics and global (in)jusltice 98 Sirrn Holm Part I: The social ethica, and politica challenge negected diseases SThe enduring risis in neglected diseaes 109 Nithaa Ford 11. Moving eyond charity for R&D for negeted diseases 11 fanes Qibinski and Barry Ru ialh SNeglectcd disease research: health Ineds and new mod els for R& 125 dn H'ollis 13. Advanced purchase commitments: moral and practical problems 134 Dlnald l4 Light av ilability 153 Michael I SelAh lid and Elinre I. Seper 16 Fair followers: expandng access to generic ph riaceutcals for iow- and middle innscmet populations 164 te in O att son 17. Abolishing the prodct atent: a tep forward fo globa accessw to d Aiam I annan and A/lan Stry 8. Trading health for prol: the imepat of bilatea i ani regional fiee tIradt igree ments n dciiestic intelleitial ptopeti) ruies on pharmaccut icts 90 Aisa Tor ian Part V: Research ethics 9 tiumian genormic researclih ethics chaginrg the rules 203 Stcen HI Miles 20 Asturption in the "stanIard f c tare" deb ate 215 Alo ia t.ln, Part VI: PoBitica activism and treatment access 2 I e dicixes lor Ill? Cotit ment iand or proirn se in th fight fora Can adas Law on compulsory liecnsig ifr expo rt 27 Rialrd Biliiot 22. acing access to essental edicines on the human rights agenda 239 Brook K. Baker Part VII: Nationa responsibities 23 Prodcinc g aifordabie medicines in South \rica 251 Jodo . CCarapinha 4National reponsibility in the provision of basic medicines 260 kieasla 1il us , Laura Esnail, and Jillian Clare Cohen 25. Pharmacutical cost-effectiveness pricing: developing and protecting a global ideal form 2,2 Thiomas A. Faunce